Related Experiment Videos
Emerging molecular targets for the treatment of pre-eclampsia
Nigel M Page1, C Fred Kemp, Philip J Lowry
1School of Animal and Microbial Sciences, The University of Reading, Reading, RG6 6AJ, UK. sasnpage@reading.ac.uk
Insights
Pre-eclampsia (PE) is a dangerous pregnancy condition causing maternal deaths and premature births. Research is exploring complex mechanisms to develop new treatments for this life-threatening disorder.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Pathophysiology
Background:
- Pre-eclampsia (PE) is a significant cause of maternal mortality and morbidity.
- It also leads to iatrogenic prematurity, burdening families and healthcare systems.
- PE's diverse symptoms and early onset complicate diagnosis and treatment development.
Purpose of the Study:
- To review the complex pathological mechanisms underlying pre-eclampsia.
- To highlight current research findings for potential therapeutic targets.
- To explore strategies for preventing or altering the course of PE.
Main Methods:
- Literature review of current research on pre-eclampsia pathology.
- Analysis of studies investigating multi-system complications.
- Examination of emerging therapeutic targets and strategies.
Main Results:
- PE involves complex, multi-system pathological mechanisms.
- Current therapeutic interventions primarily manage symptoms (hypertension, seizures) and are inadequate.
- Emerging findings offer potential for novel preventative or disease-altering treatments.
Conclusions:
- Understanding PE's complex pathology is crucial for effective management.
- Further research into pathological mechanisms can guide the development of targeted therapies.
- New therapeutic approaches hold promise for improving outcomes in pre-eclampsia.
Abstract:
Pre-eclampsia (PE) is a pregnancy-specific syndrome that is a principal cause of maternal morbidity and mortality, accounting for almost 15% of pregnancy-associated deaths. It is also one of the major causes of iatrogenic prematurity among new born babies, placing a heavy burden on both prospective parents and on the health service. The mild form of PE most commonly presents with the features of maternal hypertension and proteinuria but can swiftly and unpredictably become severe with many extensive complications, which can involve the maternal liver, kidneys, lungs, blood and platelet coagulation and nervous systems. These clinical problems normally only become apparent in the second half of pregnancy but are believed to start during the first trimester. The diverse symptoms of PE have made it a difficult disease not only to define but also to identify a causative agent for the symptoms. It has therefore proved difficult to develop specific drugs that can be used to manage the condition in the clinic. Therapeutic intervention so far has been primarily aimed at combating the two main complications of PE - the hypertension and seizures. Current therapies are widely recognised as inadequate. This review examines the complex pathological mechanisms believed to be responsible for the multi-system complications of PE. It highlights current findings that exhibit the potential to target these effects with the aim of either preventing or altering the course of this life-threatening disease of pregnancy.